Barbosa, A.; Pinto, P.; Peixoto, A.; Guerra, J.; Pinto, C.; Santos, C.; Pinheiro, M.; Escudeiro, C.; Bartosch, C.; Silva, J.;
et al. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2. Cancers 2020, 12, 2834.
https://doi.org/10.3390/cancers12102834
AMA Style
Barbosa A, Pinto P, Peixoto A, Guerra J, Pinto C, Santos C, Pinheiro M, Escudeiro C, Bartosch C, Silva J,
et al. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2. Cancers. 2020; 12(10):2834.
https://doi.org/10.3390/cancers12102834
Chicago/Turabian Style
Barbosa, Ana, Pedro Pinto, Ana Peixoto, Joana Guerra, Carla Pinto, Catarina Santos, Manuela Pinheiro, Carla Escudeiro, Carla Bartosch, João Silva,
and et al. 2020. "Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2" Cancers 12, no. 10: 2834.
https://doi.org/10.3390/cancers12102834
APA Style
Barbosa, A., Pinto, P., Peixoto, A., Guerra, J., Pinto, C., Santos, C., Pinheiro, M., Escudeiro, C., Bartosch, C., Silva, J., & Teixeira, M. R.
(2020). Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2. Cancers, 12(10), 2834.
https://doi.org/10.3390/cancers12102834